KRAS and familial pancreatic carcinoma: In conclusion, our findings clearly indicate that the expression of oncogenic KRAS shifts the balance of DSB repair towards the highly error-prone alt-EJ pathway, and highlights the mutagenic properties of alt-EJ, making it the preferred DNA repair pathway in pancreatic cancer.